Liver Organoid Idarubicin Sensitivity Is Not Significantly Linked to TACE Response

Testing a Local Chemotherapy Question Outside the Liver

Researchers at Uppsala University studied whether liver organoid responses could help explain variation after transarterial chemoembolization, or TACE, with idarubicin. Their Scientific Reports paper linked biopsy-derived cultures to the TACTida trial, an open-label, single-center, nonrandomized active-treatment study at Uppsala University Hospital. The principal clinical finding was negative: the organoids’ idarubicin sensitivity did not significantly track the measured treatment outcomes.

The comparison included organoids from hepatocellular carcinoma and nontumor liver tissue. This pairing allowed the team to examine tumor selectivity as well as differences among tumors.

Culture Yield and Drug Sensitivity Were Both Variable

Of 65 biopsies, 42 yielded cultures: 17 of 32 tumor biopsies and 25 of 33 nontumor biopsies. At the patient level, tumor organoids were established for 15 of 28 patients and nontumor organoids for 20 of 28. Several patients contributed more than one biopsy-derived culture.

After six days of growth, organoids received idarubicin for 24 hours across concentrations from 0 to 100 μM. ATP-based viability measurements gave tumor IC50 values of 0.58–38.3 μM and nontumor values of 0.44–76.1 μM. The broad, overlapping ranges showed that the drug did not consistently favor the tumor cultures.

Across 17 matched culture comparisons, tumor organoids were more sensitive in seven, nontumor organoids were more sensitive in seven, and three showed comparable sensitivity. Live/dead staining after a separate 2.5 μM, 24-hour exposure supported a cytotoxic response but also showed variation between individual tumor and nontumor cultures.

Doxorubicin and Molecular Readouts Added Context

The Results describe a doxorubicin comparison in cultures from eight patients. Doxorubicin was tested for 24 hours over 0–500 μM. Its IC50 was 4–12.5 times the idarubicin IC50 in the reported comparisons, indicating greater idarubicin potency under these culture conditions. This concentration comparison does not establish how either drug distributes or persists during embolization.

Expression measurements in seven patients’ organoids indicated activation of several endoplasmic-reticulum stress-response branches. HSPA5, PERK, ATF4, CHOP, GADD34, IRE1α, XBP1 and EDEM1 increased, while ATF6 and HERP did not change significantly. Ki67 transcripts decreased, whereas PCNA increased; the authors interpreted the latter as a possible DNA-repair response rather than evidence of increased growth.

Secretion assays in six patients’ cultures found lower alpha-fetoprotein and higher TGF-β1 after idarubicin treatment in most cultures. Neither change was detected in one patient’s culture. These measurements characterize the response within the assay and were not validated as surrogate markers of clinical benefit.

The Clinical Association Remained Unconfirmed

Tumor-organoid IC50 did not show a significant association with tumor necrosis, mRECIST radiological response, objective response or disease control. Dividing cultures at the median IC50 of 15 μM also failed to separate clinical responders from nonresponders. The experiment therefore did not validate this short-exposure viability assay as a means of selecting patients for idarubicin TACE.

TACE combines drug delivery with vascular occlusion. A uniformly exposed organoid lacks the changing oxygen supply, heterogeneous drug deposition, retention and vascular architecture of an embolized tumor. Biopsy sampling and incomplete culture establishment introduce further selection. The study documents substantial patient-derived variation in drug response, while leaving the connection between that variation and the combined clinical procedure unresolved.